Vitespen - European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Oncophage

Withdrawals of Application - Medicinal Products for Human Use
Oncophage [Vitespen]
Withdrawal EPAR

The European Medicines Agency has been formally notified by Antigenics Therapeutics Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicine Oncophage (vitespen), 20 μg solution for infusion.

abrir aquí para acceder al documento EMEA completo:
European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Oncophage
file3848month480